Nasdaq dbtx.

Find the latest Institutional Holdings data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.... NASDAQ. 051340339, Xoma Corporation, USA, XOMA, NASDAQ. 051575309, Twist Bioscience Corporation, USA, TWST, NASDAQ. 051816227 ... DBTX, NASDAQ. 080144027, Ulta ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ...

Decibel Therapeutics Inc (NASDAQ:DBTX) reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020 to protect against hearing loss in cancer ...Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ...Decibel Therapeutics (NASDAQ:DBTX) posts positive preclinical data supporting the company’s gene therapy product candidate, DB-OTO, a potential treatment for individuals with hearing loss due to ...

May 2, 2022 · BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... August 09 2023 - 08:14AMDow Jones News. By Dean Seal. Regeneron Pharmaceuticals agreed to acquire Decibel Therapeutics for $4 a share, marking a 43% …

BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at March 2023, Decibel Therapeutics had cash of US$88m and no debt ...BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Nov 9, 2022 · BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Major Sales, Dec 2021, Decibel Therapeutics. Major sales ($100,000 or more). Decibel Therapeutics (NASDAQ: DBTX). View Major Sales. Related Products: Custom ...

Mar 21, 2023 · BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, March 18, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...August 09 2023 - 08:14AMDow Jones News. By Dean Seal. Regeneron Pharmaceuticals agreed to acquire Decibel Therapeutics for $4 a share, marking a 43% …Aug 31, 2023 · Decibel Therapeutics, Inc. (Nasdaq - DBTX) Under the terms of the Merger Agreement, Decibel will be acquired by Regeneron Pharmaceuticals, Inc. (Nasdaq - REGN). Decibel shareholders will receive ... The European Commission (EC) granted orphan drug designation to Decibel Therapeutics' (NASDAQ:DBTX) gene therapy DB-OTO to treat profound, congenital hearing loss caused by mutations of the ...(NASDAQ: DBTX), Ear Diseases; Gene Therapy, Citigroup SVB Leerink BMO Capital Markets Barclays Capital, 2/11/2021. S-1, $18, $127 million, $16 – $18 ...Director. 02/17/2021. Acquisition (Non Open Market) Indirect. 3,278,526. 2,732,106. Back to DBTX Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the ...Jun 28, 2022 · BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a ...

BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data ...Decibel Therapeutics, Inc. (NASDAQ: DBTX) Decibel Therapeutics has agreed to merge with Regeneron Pharmaceuticals. Under the proposed transaction, Decibel shareholders will receive $4.00 in cash ...BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25 th …Gainers Broadwind Inc (NASDAQ: BWEN) shares climbed 85.4% to $4.19 after the company announced the receipt of approximately $175 million in new tower orders from a leading global wind turbine ...Decibel Therapeutics, Inc. (Nasdaq - DBTX) Under the terms of the Merger Agreement, Decibel will be acquired by Regeneron Pharmaceuticals, Inc. (Nasdaq - REGN). Decibel shareholders will receive ...

Translating rapid advances in hearing science to meet the urgent needs of hundreds of millions worldwide with disabling hearing loss.16-Nov-2023 ... (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing ...

Decibel Therapeutics Inc (NASDAQ: DBTX) announced the presentation of preclinical data on DB-OTO, its lead gene therapy product candidate. DB-OTO is a dual-vector adeno-associated candidate ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Nov 2, 2022 · Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ... NASDAQ, #2023-527, (UPDATED: Merger closed) Information Regarding the Tender Offer of Decibel Therapeutics, Inc. (DBTX). Sep 18, 2023, NASDAQ, #2023-526, ( ...BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Find the latest dividend history for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.

See the latest Decibel Therapeutics Inc Ordinary Shares stock price (NASDAQ:DBTX), related news, valuation, dividends and more to help you make your investing decisions.

NASDAQ:DBTX. Decibel Therapeutics, Inc. Stock Forecast . NASDAQ Stock Exchange > Healthcare > Biotechnology Open Broker Account $4.91 +0 (+0%) At Close: Nov 29, 2023Decibel Therapeutics, Inc. (DBTX) Stock Price | Stock Quote Nasdaq - MarketScreener DECIBEL THERAPEUTICS, INC. Decibel Therapeutics, Inc. Stock price Equities DBTX …(DBTX) reported a total revenue of $12.5 million in the first quarter of 2022 ... NASDAQ · NYSE · Blog. Need Help? [email protected]. Create your mobile categories ...BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25 th …BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...May 11, 2023 · Fintel reports that on May 12, 2023, HC Wainwright & Co. reiterated coverage of Decibel Therapeutics (NASDAQ:DBTX) with a Buy recommendation. Analyst Price Forecast Suggests 272.02% Upside. As of ... TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement ...IPO lockups expire on Signify Health (SGFY), Viant Technology , Apria (APR), Bumble , Bioventus , LoanDepot , Decibel Therapeutics (NASDAQ:DBTX), NexImmune and Talis Biomedical .

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...On July 20, investment advisory Deutsche Bank maintained a Buy rating on Indie Semiconductor, Inc. (NASDAQ:INDI) stock and lowered the price target to $10 from $11. Analyst Ross Seymore issued the ...BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...NASDAQ: ALXO. age1. INVISIBLE. The Longevity Fund. INVISIBLE. The Longevity Fund. INVISIBLE. The Longevity Fund. NASDAQ: DBTX.Instagram:https://instagram. groundfloor.us reviewex date dividend calendarforex for mact rowe price all cap opportunities The Decibel Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Based on analysts offering 12 month price targets for DBTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . yieldmax tsla option income strategy etflegit forex trading platform BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... mon coer Nov 30, 2023 · Financial Performance. In 2022, REGN's revenue was $12.17 billion, a decrease of -24.26% compared to the previous year's $16.07 billion. Earnings were $4.34 billion, a decrease of -46.28%. Financial Statements. BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...